These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 36259869)

  • 21. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata.
    Kennedy Crispin M; Ko JM; Craiglow BG; Li S; Shankar G; Urban JR; Chen JC; Cerise JE; Jabbari A; Winge MC; Marinkovich MP; Christiano AM; Oro AE; King BA
    JCI Insight; 2016 Sep; 1(15):e89776. PubMed ID: 27699252
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic synergy between contact dermatitis from a wig-fixing device and tofacitinib on alopecia areata.
    Lee JS; Yoon HS; Cho S; Park HS
    J Dermatol; 2019 Apr; 46(4):e139-e140. PubMed ID: 30204259
    [No Abstract]   [Full Text] [Related]  

  • 23. Treatment of Alopecia Areata With Tofacitinib.
    Ibrahim O; Bayart CB; Hogan S; Piliang M; Bergfeld WF
    JAMA Dermatol; 2017 Jun; 153(6):600-602. PubMed ID: 28355451
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nail involvement in patients with moderate-to-severe alopecia areata treated with oral tofacitinib.
    Lee JS; Huh CH; Kwon O; Yoon HS; Cho S; Park HS
    J Dermatolog Treat; 2018 Dec; 29(8):819-822. PubMed ID: 29658800
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tofacitinib therapy for children with severe alopecia areata.
    Dai YX; Chen CC
    J Am Acad Dermatol; 2019 Apr; 80(4):1164-1166. PubMed ID: 30630026
    [No Abstract]   [Full Text] [Related]  

  • 26. Tofacitinib for the treatment of alopecia areata and variants in adolescents.
    Craiglow BG; Liu LY; King BA
    J Am Acad Dermatol; 2017 Jan; 76(1):29-32. PubMed ID: 27816292
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral tofacitinib for successful treatment of refractory alopecia areata in preschool children.
    Geng SL; Gong T; Ji C; Su HH
    J Eur Acad Dermatol Venereol; 2022 Dec; 36(12):e1055-e1057. PubMed ID: 35876014
    [No Abstract]   [Full Text] [Related]  

  • 28. A Case Report Highlighting the Effective Treatment of Alopecia Universalis With Tofacitinib in an Adolescent and Adult Patient.
    Patel NU; Oussedik E; Grammenos A; Pichardo-Geisinger R
    J Cutan Med Surg; 2018; 22(4):439-442. PubMed ID: 29463114
    [No Abstract]   [Full Text] [Related]  

  • 29. Treatment of alopecia universalis with topical Janus kinase inhibitors - a double blind, placebo, and active controlled pilot study.
    Bokhari L; Sinclair R
    Int J Dermatol; 2018 Dec; 57(12):1464-1470. PubMed ID: 30160787
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of tofacitinib in treatment of alopecia universalis in two patients.
    Gupta AK; Carviel JL; Abramovits W
    J Eur Acad Dermatol Venereol; 2016 Aug; 30(8):1373-8. PubMed ID: 27306107
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents.
    Liu LY; King BA
    J Investig Dermatol Symp Proc; 2018 Jan; 19(1):S18-S20. PubMed ID: 29273099
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tofacitinib for the Treatment of Three Immune-mediated Conditions in One Patient: Ulcerative Colitis, Pyoderma Gangrenosum, and Alopecia Areata.
    Sedano R; Jairath V
    Inflamm Bowel Dis; 2021 Apr; 27(5):e65. PubMed ID: 33484124
    [No Abstract]   [Full Text] [Related]  

  • 33. Correlation between serum granulysin level and clinical activity in patients with alopecia areata before and after tofacitinib therapy.
    Oba MC; Askin O; Balci Ekmekci O; Serdaroglu S
    J Cosmet Dermatol; 2021 Mar; 20(3):971-975. PubMed ID: 32808476
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factors associated with insurance coverage of tofacitinib for alopecia areata: A retrospective review from an academic institution.
    Thompson HJ; Vavra T; Jabbari A
    J Am Acad Dermatol; 2020 Nov; 83(5):1509-1510. PubMed ID: 32553634
    [No Abstract]   [Full Text] [Related]  

  • 35. Tofacitinib for the treatment of alopecia areata in preadolescent children.
    Craiglow BG; King BA
    J Am Acad Dermatol; 2019 Feb; 80(2):568-570. PubMed ID: 30195571
    [No Abstract]   [Full Text] [Related]  

  • 36. Hair transplantation for therapy-resistant alopecia areata of the eyebrows: is it the right choice?
    Civaş E; Aksoy B; Aksoy HM; Eski M; Yucel K
    J Dermatol; 2010 Sep; 37(9):823-6. PubMed ID: 20883369
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rapidly progressive alopecia areata totalis in a COVID-19 patient, unresponsive to tofacitinib.
    Berbert Ferreira S; Gavazzoni Dias MFR; Berbert Ferreira R; Neves Neto AC; Trüeb RM; Lupi O
    J Eur Acad Dermatol Venereol; 2021 Jul; 35(7):e411-e412. PubMed ID: 33587766
    [No Abstract]   [Full Text] [Related]  

  • 38. Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo.
    Vu M; Heyes C; Robertson SJ; Varigos GA; Ross G
    Clin Exp Dermatol; 2017 Dec; 42(8):942-944. PubMed ID: 29034491
    [No Abstract]   [Full Text] [Related]  

  • 39. Systematic review - alopecia areata and tofacitinib in paediatric patients.
    Bandeira A; Albino-Teixeira A; Magina S
    Cutan Ocul Toxicol; 2022 Jun; 41(2):194-201. PubMed ID: 35687530
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.